Ventyx Biosciences Announces Positive Results From Phase 2 Trial Of VTX3232 For Obesity, Cardiovascular Risk Factors; Vtx3232 Monotherapy Achieved ~80% Reduction In Hscrp; Vtx3232 Monotherapy Reduced Il-6 Levels

Author: Benzinga Newsdesk | October 22, 2025 04:05pm

Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), today announced positive results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk Factors. The 175- participant study examined VTX3232 versus placebo, alone or in combination with semaglutide, evaluating safety and tolerability as the primary endpoint, and effects on inflammation (measured by high-sensitivity C-reactive protein or hsCRP) as the secondary endpoint.   

Participants treated with VTX3232 monotherapy in the modified analysis set ("MAS")2 showed a 78% reduction in hsCRP at week 12 relative to baseline compared with a 3% increase in the placebo group (p<0.0001). Participants treated with VTX3232 in the full analysis set ("FAS")3 showed a 64% reduction in hsCRP at week 12 relative to baseline compared with a 3% increase in the placebo group (p<0.0001). Participants treated with VTX3232 monotherapy also showed statistically significant reductions in IL-6 (p<0.0001) to levels associated with reduced cardiovascular risk (IL-6 ≤1.65ng/L)1.

Posted In: VTYX